CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Colchicine 1 MG Oral TabletWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1351 nasopharyngeal Covid 19 RT-PCR Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D006528 Carcinoma, Hepatocellular NIH 1.00
D002277 Carcinoma NIH 0.71

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0001402 Hepatocellular carcinoma HPO 1.00
HP:0030731 Carcinoma HPO 0.71

There is one clinical trial.

Clinical Trials

1 Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study

This is an interventional, pilot, multicenter, randomized, open-label, phase 2 study, enrolling patients with COVID-19 disease. One-month rate of entering the critical stage (either a. Respiratory failure occurs and requires mechanical ventilation; b. Patients combined with other organ failure need ICU monitoring and treatment; c. Death) is the primary endpoint.

NCT04375202 COVID-19 Drug: Colchicine 1 MG Oral Tablet

Primary Outcomes

Description: Comply with any of the followings: Respiratory failure occurs and requires mechanical ventilation; Patients combined with other organ failure need ICU monitoring and treatment Death

Measure: Rate of entering the critical stage

Time: [1 month]

Secondary Outcomes

Measure: Trend of White blood cell count

Time: [up to 30 days]

Measure: Change of the "Sequential Organ failure Assessment" (SOFA)

Time: [up to 30 days]

Measure: Rate of biochemical criterion (CK, ALT, ferritin) recovery

Time: [up to 30 days]

Description: Comply with any of the followings: No fever, cough and other symptoms; SPO2>94% or PaO2/FiO2 >350mmHg without oxygen inhalation

Measure: Rate of disease remission

Time: [up to 30 days]

Description: Rate of adverse events codified by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Measure: Toxicity of Colchicine

Time: [up to 30 days]

No related HPO nodes (Using clinical trials)